Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 5, 2009, Pages 569-573

  Geretti, Anna Maria ^a   Fox, Zoe V ^a   Booth, Clare L ^a   Smith, Colette J ^a   Phillips, Andrew N ^a   Johnson, Margaret ^a   Li, Jin Fen ^b   Heneine, Walid ^b   Johnson, Jeffrey A ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Efavirenz; Low frequency mutants; Nevirapine; Transmitted drug resistance

Indexed keywords

ABACAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MUTATION; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 73349116621     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ba11e8     Document Type: Article

References (27)

1. Masquelier B, Bhaskaran K, Pillay D, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr. 2005;40:505-511.
2. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-966.
3. Booth CL, Garcia-Diaz AM, Youle MS, et al. Prevalence and predictors of transmitted antiretroviral resistance in newly diagnosed HIV-1 infection. J Antimicrob Chem. 2007;59:517-524.
4. Geretti AM. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis. 2007;20:22-32
5. SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS. 2008;22:625-635.
6. Vercauteren J, Derdelinckx I, Sasse A, et al. Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses. 2008;24:355-362.
7. Peuchant O, Thiébaut R, Capdepont S, et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS. 2008;22:1417-1423.
8. Bannister WP, Cozzi-Lepri A, Clotet B, et al. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr. 2008;48:324-333.
9. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174-2180.
10. Pillay D, Bhaskaran K, Jurriaans S, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS. 2006,20:21-28.
11. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
12. Violin M, Cozzi-Lepri A, Velleca R, et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS. 2004;18:227-235.
13. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008;197:867-870.
14. Gunthard HF, Wong JK, Ignacio CC, et al. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses. 1998;14:869-876.
15. Bezemer D, de Ronde A, Prins M, et al. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther. 2006;11:173-178.
16. Metzner KJ, Rauch P, Walter H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS. 2005;19:1819-1825.
17. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43:406-413.
18. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005;192:16-23.
19. Johnson JA, Li J-F, Wei X, et al. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS ONE. 2007;2:e638.
20. Johnson JA, Li J-F, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008;5:e158.
21. Metzner KJ, Rauch P, Von Wyl V, et al. Prevalence of minority quasispecies of drug-resistant HIV-1 in patients with primary HIV-1 infection in Zurich in the years 2002-2006. Antivir Ther. 2007;12:S47.
22. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-2106.
23. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007; 356:135-147.
24. Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther. 2004,2:147-151.
25. Dunn D, Geretti AM, Green H, et al. Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Antivir Ther. 2008;13:771-777.
26. Kolber MA. Development of drug resistance mutations in patients on highly active antiretroviral therapy: does competitive advantage drive evolution. AIDS Rev. 2007;9:68-74.
27. Gazzard BG, BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563-608.